Catalog10 refs
Liraglutide
Metabolicglp1Weight LossResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
Liraglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Victoza, 1.8 mg daily) and chronic weight management (Saxenda, 3.0 mg daily). As a predecessor to semaglutide, liraglutide was the first GLP-1 agonist approved specifically for obesity. It shares the same mechanism of action as semaglutide but requires daily rather than weekly dosing due to its shorter half-life (~13 hours). With the largest long-term safety dataset of any GLP-1 agonist and landmark cardiovascular outcomes data from the LEADER trial, liraglutide remains a clinically important reference point in the rapidly evolving incretin therapy landscape.
Primary Uses
Type 2 diabetes management
Weight management
Appetite suppression and satiety enhancement
Glucose control
Cardiovascular risk reduction
Chronic weight management
Adolescent obesity (ages 12+)
Cardiovascular risk reduction in type 2 diabetes
Weight-management research
Cardiometabolic studies
GLP-1 pharmacology
Type 2 diabetes
Blood glucose reduction
Weight loss
Insulin secretion
Glucagon inhibition
Cardiovascular benefits
Protocol Reference
Dose
0.6–3.0mg/day (titrated weekly)
Frequency
Daily
Half-life
Approximately 13 Hours
Route
Injection
Evidence
FDA Approved / Phase 4, FDA Approved / FDA-approved; landmark clinical trials (LEADER, SCALE) / FDA-approved (disputed)
Research References· 20
https://pubmed.ncbi.nlm.nih.gov/27295427/
PubMedPMID 27295427- [https://www.nejm.org/doi/full/10.1056/NEJMoa1603827](https://www.nejm.org/doi/full/10.1056/NEJMoa1603827)
insulin degludec with liraglutide↗
DOI- Crossref
Research Models
HumanMouse
Also in Metabolic